These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The Potential of Steroid Profiling by Mass Spectrometry in the Management of Adrenocortical Carcinoma. Rossi C; Cicalini I; Verrocchio S; Di Dalmazi G; Federici L; Bucci I Biomedicines; 2020 Aug; 8(9):. PubMed ID: 32872281 [TBL] [Abstract][Full Text] [Related]
24. Early Detection of Recurrence and Progress Using Serum Steroid Profiling by LC-MS/MS in Patients with Adrenocortical Carcinoma. Kimpel O; Altieri B; Dischinger U; Fuss CT; Kurlbaum M; Fassnacht M Metabolites; 2023 Dec; 14(1):. PubMed ID: 38248823 [TBL] [Abstract][Full Text] [Related]
25. Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma. Velikanova LI; Shafigullina ZR; Lisitsin AA; Vorokhobina NV; Grigoryan K; Kukhianidze EA; Strelnikova EG; Krivokhizhina NS; Krasnov LM; Fedorov EA; Sablin IV; Moskvin AL; Bessonova EA Horm Cancer; 2016 Dec; 7(5-6):327-335. PubMed ID: 27370636 [TBL] [Abstract][Full Text] [Related]
26. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas. Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173 [TBL] [Abstract][Full Text] [Related]
28. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456 [TBL] [Abstract][Full Text] [Related]
29. Urinary steroid profiling in diagnostic evaluation of an unusual adrenal mass. Lenders NF; Greenfield JR Endocrinol Diabetes Metab Case Rep; 2019 Nov; 2019():. PubMed ID: 31778357 [TBL] [Abstract][Full Text] [Related]
30. Targeted metabolic profiling of urinary steroids with a focus on analytical accuracy and sample stability. Vogg N; Müller T; Floren A; Dandekar T; Scherf-Clavel O; Fassnacht M; Kroiss M; Kurlbaum M J Mass Spectrom Adv Clin Lab; 2022 Aug; 25():44-52. PubMed ID: 35910411 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors. Kerkhofs TM; Kerstens MN; Kema IP; Willems TP; Haak HR Horm Cancer; 2015 Aug; 6(4):168-75. PubMed ID: 25985881 [TBL] [Abstract][Full Text] [Related]
32. Gynecomastia in a Man With Adrenal Mass. Saini J; Navin P; Rivera M; Bancos I JCEM Case Rep; 2024 Jan; 2(1):luad143. PubMed ID: 38192879 [TBL] [Abstract][Full Text] [Related]
33. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas. Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493 [TBL] [Abstract][Full Text] [Related]